Pilot study of vascular health in survivors of osteosarcoma

Daniel A. Mulrooney, Kirsten K. Ness, Sujuan Huang, Anna Solovey, Robert P. Hebbel, James D. Neaton, Denis R. Clohisy, Aaron S. Kelly, Joseph P. Neglia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Cardiovascular-related toxicities have been reported among survivors of osteosarcoma. Methods: Fasting blood samples from 24 osteosarcoma survivors were analyzed for high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein-ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and surface expression of vascular cell adhesion molecule-1 (VCAM-1). Values were compared to subjects in the natural history Coronary Artery Risk Development in Young Adults (CARDIA) cohort study except for CECs and VCAM-1 expression, which were compared to controls studied at the University of Minnesota Lillehei clinical trials unit. Procedure: Survivors (54.2% male), median age 18 years (9-32) at diagnosis, 36.5 years (20-56) at evaluation were treated with a variety of chemotherapeutic exposures, all but one were exposed to doxorubicin (median dose 450mg/m2; range: 90-645mg/m2), 14 (58.3%) received cisplatin, and 3 (12.5%) were exposed to carboplatin. Two survivors (8.3%) received radiation therapy for disease relapse. Compared to CARDIA subjects, mean hsCRP (3.0mg/L±2.0 vs. 1.6±2.3), triglycerides (151mg/dl±81.7 vs. 95.4±101.3), lipoprotein (a) (34.9mg/dl±17.7 vs. 13.8±22.0), and fibrinogen (315.0mg/dl±49.3 vs. 252.4±61.7) were significantly elevated. The number of CECs (0.47cells/ml±2.5 vs. 0.92±2.5) did not differ while surface expression of VCAM-1 (86.4%±34.0 vs. 42.1±33.8) was significantly elevated compared to controls. Conclusions: Among survivors of osteosarcoma, assessed a median of 14 years from diagnosis, there is evidence of vascular inflammation, dyslipidemia, and early atherogenesis. Pediatr Blood Cancer 2013;60:1703-1708.

Original languageEnglish (US)
Pages (from-to)1703-1708
Number of pages6
JournalPediatric Blood and Cancer
Volume60
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Vascular Cell Adhesion Molecule-1
Osteosarcoma
Blood Vessels
Lipoprotein(a)
Endothelial Cells
C-Reactive Protein
Fibrinogen
Young Adult
Coronary Vessels
Health
Triglycerides
Apolipoproteins
Carboplatin
Dyslipidemias
Natural History
Doxorubicin
HDL Cholesterol
Cisplatin
Fasting
Atherosclerosis

Keywords

  • Osteosarcoma
  • Survivorship
  • Vascular late effects

Cite this

Pilot study of vascular health in survivors of osteosarcoma. / Mulrooney, Daniel A.; Ness, Kirsten K.; Huang, Sujuan; Solovey, Anna; Hebbel, Robert P.; Neaton, James D.; Clohisy, Denis R.; Kelly, Aaron S.; Neglia, Joseph P.

In: Pediatric Blood and Cancer, Vol. 60, No. 10, 01.10.2013, p. 1703-1708.

Research output: Contribution to journalArticle

@article{ec71664e643e4d45960a0ac5bb516342,
title = "Pilot study of vascular health in survivors of osteosarcoma",
abstract = "Background: Cardiovascular-related toxicities have been reported among survivors of osteosarcoma. Methods: Fasting blood samples from 24 osteosarcoma survivors were analyzed for high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein-{\ss}, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and surface expression of vascular cell adhesion molecule-1 (VCAM-1). Values were compared to subjects in the natural history Coronary Artery Risk Development in Young Adults (CARDIA) cohort study except for CECs and VCAM-1 expression, which were compared to controls studied at the University of Minnesota Lillehei clinical trials unit. Procedure: Survivors (54.2{\%} male), median age 18 years (9-32) at diagnosis, 36.5 years (20-56) at evaluation were treated with a variety of chemotherapeutic exposures, all but one were exposed to doxorubicin (median dose 450mg/m2; range: 90-645mg/m2), 14 (58.3{\%}) received cisplatin, and 3 (12.5{\%}) were exposed to carboplatin. Two survivors (8.3{\%}) received radiation therapy for disease relapse. Compared to CARDIA subjects, mean hsCRP (3.0mg/L±2.0 vs. 1.6±2.3), triglycerides (151mg/dl±81.7 vs. 95.4±101.3), lipoprotein (a) (34.9mg/dl±17.7 vs. 13.8±22.0), and fibrinogen (315.0mg/dl±49.3 vs. 252.4±61.7) were significantly elevated. The number of CECs (0.47cells/ml±2.5 vs. 0.92±2.5) did not differ while surface expression of VCAM-1 (86.4{\%}±34.0 vs. 42.1±33.8) was significantly elevated compared to controls. Conclusions: Among survivors of osteosarcoma, assessed a median of 14 years from diagnosis, there is evidence of vascular inflammation, dyslipidemia, and early atherogenesis. Pediatr Blood Cancer 2013;60:1703-1708.",
keywords = "Osteosarcoma, Survivorship, Vascular late effects",
author = "Mulrooney, {Daniel A.} and Ness, {Kirsten K.} and Sujuan Huang and Anna Solovey and Hebbel, {Robert P.} and Neaton, {James D.} and Clohisy, {Denis R.} and Kelly, {Aaron S.} and Neglia, {Joseph P.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1002/pbc.24610",
language = "English (US)",
volume = "60",
pages = "1703--1708",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Pilot study of vascular health in survivors of osteosarcoma

AU - Mulrooney, Daniel A.

AU - Ness, Kirsten K.

AU - Huang, Sujuan

AU - Solovey, Anna

AU - Hebbel, Robert P.

AU - Neaton, James D.

AU - Clohisy, Denis R.

AU - Kelly, Aaron S.

AU - Neglia, Joseph P.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Cardiovascular-related toxicities have been reported among survivors of osteosarcoma. Methods: Fasting blood samples from 24 osteosarcoma survivors were analyzed for high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein-ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and surface expression of vascular cell adhesion molecule-1 (VCAM-1). Values were compared to subjects in the natural history Coronary Artery Risk Development in Young Adults (CARDIA) cohort study except for CECs and VCAM-1 expression, which were compared to controls studied at the University of Minnesota Lillehei clinical trials unit. Procedure: Survivors (54.2% male), median age 18 years (9-32) at diagnosis, 36.5 years (20-56) at evaluation were treated with a variety of chemotherapeutic exposures, all but one were exposed to doxorubicin (median dose 450mg/m2; range: 90-645mg/m2), 14 (58.3%) received cisplatin, and 3 (12.5%) were exposed to carboplatin. Two survivors (8.3%) received radiation therapy for disease relapse. Compared to CARDIA subjects, mean hsCRP (3.0mg/L±2.0 vs. 1.6±2.3), triglycerides (151mg/dl±81.7 vs. 95.4±101.3), lipoprotein (a) (34.9mg/dl±17.7 vs. 13.8±22.0), and fibrinogen (315.0mg/dl±49.3 vs. 252.4±61.7) were significantly elevated. The number of CECs (0.47cells/ml±2.5 vs. 0.92±2.5) did not differ while surface expression of VCAM-1 (86.4%±34.0 vs. 42.1±33.8) was significantly elevated compared to controls. Conclusions: Among survivors of osteosarcoma, assessed a median of 14 years from diagnosis, there is evidence of vascular inflammation, dyslipidemia, and early atherogenesis. Pediatr Blood Cancer 2013;60:1703-1708.

AB - Background: Cardiovascular-related toxicities have been reported among survivors of osteosarcoma. Methods: Fasting blood samples from 24 osteosarcoma survivors were analyzed for high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein-ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and surface expression of vascular cell adhesion molecule-1 (VCAM-1). Values were compared to subjects in the natural history Coronary Artery Risk Development in Young Adults (CARDIA) cohort study except for CECs and VCAM-1 expression, which were compared to controls studied at the University of Minnesota Lillehei clinical trials unit. Procedure: Survivors (54.2% male), median age 18 years (9-32) at diagnosis, 36.5 years (20-56) at evaluation were treated with a variety of chemotherapeutic exposures, all but one were exposed to doxorubicin (median dose 450mg/m2; range: 90-645mg/m2), 14 (58.3%) received cisplatin, and 3 (12.5%) were exposed to carboplatin. Two survivors (8.3%) received radiation therapy for disease relapse. Compared to CARDIA subjects, mean hsCRP (3.0mg/L±2.0 vs. 1.6±2.3), triglycerides (151mg/dl±81.7 vs. 95.4±101.3), lipoprotein (a) (34.9mg/dl±17.7 vs. 13.8±22.0), and fibrinogen (315.0mg/dl±49.3 vs. 252.4±61.7) were significantly elevated. The number of CECs (0.47cells/ml±2.5 vs. 0.92±2.5) did not differ while surface expression of VCAM-1 (86.4%±34.0 vs. 42.1±33.8) was significantly elevated compared to controls. Conclusions: Among survivors of osteosarcoma, assessed a median of 14 years from diagnosis, there is evidence of vascular inflammation, dyslipidemia, and early atherogenesis. Pediatr Blood Cancer 2013;60:1703-1708.

KW - Osteosarcoma

KW - Survivorship

KW - Vascular late effects

UR - http://www.scopus.com/inward/record.url?scp=84881539670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881539670&partnerID=8YFLogxK

U2 - 10.1002/pbc.24610

DO - 10.1002/pbc.24610

M3 - Article

C2 - 23720361

AN - SCOPUS:84881539670

VL - 60

SP - 1703

EP - 1708

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -